Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Magpie Pharma Reports Results from Phase II Trial of ALS Therapy

publication date: Oct 2, 2023

Guangzhou Magpie Pharma reported its lead candidate, TBN, improved some key markers of ALS disease progression in a China Phase II trial, though it did not meet the trial’s endpoints. TBN statistically improved Grip Strength (32.4%, P=0.037), a quality of life measurement that no other ALS therapy has provided, though Magpie’s candidate did not improve the broader endpoints: changes in the ALSFRS-R score and forced vital capacity. Magpie has also conducted successful Phase II trials of TBN – a multi-functional tetramethylpyrazine nitrone candidate – in patients with acute ischemic stroke and diabetic kidney disease. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital